What is the ticker symbol for uniQure N.V.?

uniQure N.V. trades under the ticker QURE on NASDAQ.

What sector does uniQure N.V. operate in?

uniQure N.V. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze QURE in a portfolio?

PortView shows QURE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

uniQure N.V. (QURE) Stock Analysis

NASDAQHealthcareBiotechnology

$46.37-3.11%

1-year price historyRange $9.03 – $70.59

52-week range$46.37

$8.73$71.50

What uniQure N.V. does

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Key metrics

Market cap

$3.22B

P/E (TTM)

-11.56

EPS (TTM)

$-4.01

Beta

0.94

Dividend yield

0.00%

Revenue / share

$0.28

50-day avg

$44.64

200-day avg

$28.13

52-week high

$71.50

52-week low

$8.73

CEO

Matthew C. Kapusta

ETFs linked to QURE

Broad-market and Healthcare sector ETFs an investor holding uniQure N.V. is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how QURE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze QURE in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for uniQure N.V.?: uniQure N.V. trades under the ticker QURE on NASDAQ.
Which exchange is QURE listed on?: QURE is listed on NASDAQ.
What sector does uniQure N.V. operate in?: uniQure N.V. is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze QURE in a portfolio?: PortView shows QURE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.